Fri Feb 21 14:20:00 UTC 2025: ## Hims & Hers Expands Services with Acquisition of At-Home Lab Testing Facility
**NEW YORK** – Telehealth company Hims & Hers announced Wednesday the acquisition of Trybe Labs, a New Jersey-based at-home lab testing facility. This acquisition significantly expands Hims & Hers’ service offerings, allowing them to provide users with at-home blood draws and more comprehensive pre-treatment testing.
The deal, funded with existing cash reserves, will enable Hims & Hers to offer testing for LDL cholesterol, lipoprotein(a), cholesterol, and apolipoprotein. This expansion will support a wider range of treatments, including those for low testosterone and perimenopausal and menopausal support. The company will utilize anonymized data from blood tests to further develop its AI-powered healthcare platform.
“Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient,” said Dr. Patrick Carroll, Hims & Hers chief medical officer. He added that at-home lab testing is a step towards “elevating the personal, comprehensive care customers…should expect.”
Hims & Hers will utilize the FDA-cleared Tasso lancet for blood collection, a single-use device that collects blood samples via a simple, button-activated process. Pricing for the new testing services will be announced within the next year.
This acquisition positions Hims & Hers as a competitor to established blood-drawing services like Labcorp and Quest Diagnostics. The move comes less than a year after the company began offering GLP-1 weight loss drugs and follows a recent Super Bowl ad criticizing the pharmaceutical industry’s pricing practices. The company’s stock price soared over 20% following the announcement, adding to a 141% increase already seen in 2025.
First Piper 